Metabolic Syndrome Is Associated With More Pronounced Impairment of Left Ventricle Geometry and Function in Patients With Calcific Aortic Stenosis. A Substudy of the ASTRONOMER (Aortic Stenosis Progression Observation Measuring Effects of Rosuvastatin)

Journal of the American College of Cardiology

Volumn 55, Issue 17, 2010, Pages 1867-1874

  Pagé, Anik ^a   Dumesnil, Jean G ^a   Clavel, Marie Annick ^a   Chan, Kwan L ^b   Teo, Koon K ^d   Tam, James W ^c   Mathieu, Patrick ^a   Després, Jean Pierre ^a   Pibarot, Philippe ^a  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^c ST BONIFACE GENERAL HOSPITAL   (Canada)

^d MCMASTER UNIVERSITY   (Canada)

Author keywords

aortic stenosis; LV function; LV remodeling; obesity

Indexed keywords

LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; AORTA STENOSIS; ARTERY CALCIFICATION; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOPPLER ECHOCARDIOGRAPHY; EDUCATION PROGRAM; FEMALE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART VENTRICLE FUNCTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PREVALENCE; PRIORITY JOURNAL;

AORTIC VALVE STENOSIS; CALCINOSIS; FEMALE; HEART VENTRICLES; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; VENTRICULAR DYSFUNCTION; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 77950879602     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2009.11.083     Document Type: Article

References (37)

1. Despres J.P., and Lemieux I. Abdominal obesity and metabolic syndrome. Nature 444 (2006) 881-887
2. Gami A.S., Witt B.J., Howard D.E., et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 49 (2007) 403-414
3. Katz R., Wong N.D., Kronmal R., et al. Features of the metabolic syndrome and diabetes mellitus as predictors of aortic valve calcification in the Multi-Ethnic Study of Atherosclerosis. Circulation 113 (2006) 2113-2119
4. Katz R., Budoff M.J., Takasu J., et al. Relationship of metabolic syndrome to incident aortic valve calcium and aortic valve calcium progression: the Multi-Ethnic Study of Atherosclerosis. Diabetes 58 (2009) 813-819
5. Briand M., Lemieux I., Dumesnil J.G., et al. Metabolic syndrome negatively influences disease progression and prognosis in aortic stenosis. J Am Coll Cardiol 47 (2006) 2229-2237
6. Safar M.E., Thomas F., Blacher J., et al. Metabolic syndrome and age-related progression of aortic stiffness. J Am Coll Cardiol 47 (2006) 72-75
7. Briand M., Pibarot P., Despres J.P., et al. Metabolic syndrome is associated with faster degeneration of bioprosthetic valves. Circulation 114 (2006) I512-I517
8. Raher M.J., Thibault H.B., Buys E.S., et al. A short duration of high-fat diet induces insulin resistance and predisposes to adverse left ventricular remodeling after pressure overload. Am J Physiol Heart Circ Physiol 295 (2008) H2495-H2502
9. Akki A., and Seymour A.M. Western diet impairs metabolic remodelling and contractile efficiency in cardiac hypertrophy. Cardiovasc Res 3 (2009) 610-617
10. Chan K.L., Teo K., Tam J., and Dumesnil J.G. Rationale, design, and baseline characteristics of a randomized trial to assess the effect of cholesterol lowering on the progression of aortic stenosis: the Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin (ASTRONOMER) trial. Am Heart J 153 (2007) 925-931
11. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., and Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-419
12. Expert Panel. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2492
13. Rosenhek R., Binder T., Porenta G., et al. Predictors of outcome in severe, asymptomatic aortic stenosis. N Engl J Med 343 (2000) 611-617
14. de Simone G., Devereux R.B., Daniels S.R., Koren M.J., Meyer R.A., and Laragh J.H. Effect of growth on variability of left ventricular mass: assessment of allometric signals in adults and children and their capacity to predict cardiovascular risk. J Am Coll Cardiol 25 (1995) 1056-1062
15. Ganau A., Devereux R.B., Roman M.J., et al. Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. J Am Coll Cardiol 19 (1992) 1550-1558
16. Cramariuc D., Cioffi G., Rieck A.E., et al. Low-flow aortic stenosis in asymptomatic patients: valvular arterial impedance and systolic function from the SEAS substudy. J Am Coll Cardiol Img 2 (2009) 390-399
17. Jassal D.S., Tam J.W., Dumesnil J.G., et al. Clinical usefulness of tissue doppler imaging in patients with mild to moderate aortic stenosis: a substudy of the aortic stenosis progression observation measuring effects of rosuvastatin study. J Am Soc Echocardiogr 21 (2008) 1023-1027
18. Briand M., Dumesnil J.G., Kadem L., et al. Reduced systemic arterial compliance impacts significantly on left ventricular afterload and function in aortic stenosis: implications for diagnosis and treatment. J Am Coll Cardiol 46 (2005) 291-298
19. Gerdts E., Cramariuc D., de Simone G., Wachtell K., Dahlof B., and Devereux R.B. Impact of left ventricular geometry on prognosis in hypertensive patients with left ventricular hypertrophy (the LIFE study). Eur J Echocardiogr 9 (2008) 809-815
20. Dumesnil J.G., and Shoucri R.M. Effect of the geometry of the left ventricle on the calculation of ejection fraction. Circulation 65 (1982) 91-98
21. Aurigemma G.P., Silver K.H., McLaughlin M., Mauser J., and Gaasch W.H. Impact of chamber geometry and gender on left ventricular systolic function in patients over 60 years of age with aortic stenosis. Am J Cardiol 74 (1994) 794-798
22. Orsinelli D.A., Aurigemma G.P., Battista S., Krendel S., and Gaasch W.H. Left ventricular hypertrophy and mortality after aortic valve replacement for aortic stenosis. A high-risk subgroup identified by preoperative relative wall thickness. J Am Coll Cardiol 22 (1993) 1679-1683
23. Duncan A.I., Lowe B.S., Garcia M.J., et al. Influence of concentric left ventricular remodeling on early mortality after aortic valve replacement. Ann Thorac Surg 85 (2008) 2030-2039
24. de Simone G., Palmieri V., Bella J.N., et al. Association of left ventricular hypertrophy with metabolic risk factors: the HyperGEN study. J Hypertens 20 (2002) 323-331
25. Chinali M., Devereux R.B., Howard B.V., et al. Comparison of cardiac structure and function in American Indians with and without the metabolic syndrome (the Strong Heart Study). Am J Cardiol 93 (2004) 40-44
26. Peterson L.R., Waggoner A.D., Schechtman K.B., et al. Alterations in left ventricular structure and function in young healthy obese women: assessment by echocardiography and tissue Doppler imaging. J Am Coll Cardiol 43 (2004) 1399-1404
27. Poirier P., Bogaty P., Garneau C., Marois L., and Dumesnil J.G. Diastolic dysfunction in normotensive men with well-controlled type 2 diabetes: importance of maneuvers in echocardiographic screening for preclinical diabetic cardiomyopathy. Diabetes Care 24 (2001) 5-10
28. Aijaz B., Ammar K.A., Lopez-Jimenez F., Redfield M.M., Jacobsen S.J., and Rodeheffer R.J. Abnormal cardiac structure and function in the metabolic syndrome: a population-based study. Mayo Clin Proc 83 (2008) 1350-1357
29. Mathieu P., Poirier P., Pibarot P., Lemieux I., and Despres J.P. Visceral obesity: the link among inflammation, hypertension, and cardiovascular disease. Hypertension 53 (2009) 577-584
30. Sironi A.M., Pingitore A., Ghione S., et al. Early hypertension is associated with reduced regional cardiac function, insulin resistance, epicardial, and visceral fat. Hypertension 51 (2008) 282-288
31. Worthley M.I., Curtis M.J., Goodhart D.M., and Anderson T.J. Obesity is associated with impaired human coronary endothelial function. Obes Res Clin Pract 3 (2009) 9-15
32. Taha M., and Lopaschuk G.D. Alterations in energy metabolism in cardiomyopathies. Ann Med 39 (2007) 594-607
33. Tuunanen H., Ukkonen H., and Knuuti J. Myocardial fatty acid metabolism and cardiac performance in heart failure. Curr Cardiol Rep 10 (2008) 142-148
34. Akki A., Smith K., and Seymour A.M. Compensated cardiac hypertrophy is characterised by a decline in palmitate oxidation. Mol Cell Biochem 311 (2008) 215-224
35. Unger R.H. Lipotoxic diseases. Annu Rev Med 53 (2002) 319-336
36. Lopaschuk G.D. Metabolic abnormalities in the diabetic heart. Heart Fail Rev 7 (2002) 149-159
37. Lopaschuk G.D., Folmes C.D., and Stanley W.C. Cardiac energy metabolism in obesity. Circ Res 101 (2007) 335-347